#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Laryngeal squamous cell carcinoma Macular telangiectasia Niemann-Pick disease Ovarian cancer stage IV Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Congenital disorder of glycosylation Pneumonia Uveitis Keratosis follicular Raynaud's phenomenon Deafness bilateral Pleomorphic liposarcoma Cutaneous T-cell lymphoma recurrent Salivary gland cancer Plasma cell myeloma More trials…

    Learn about Rare Diseases

    Metachromatic leukodystrophy – Basic Information Gaucher’s disease type I Encephalitis autoimmune – Basic Information Mucopolysaccharidosis III Sjogren’s syndrome – Diagnostics Haemolytic uraemic syndrome – Diagnostics Hepatoblastoma – Treatment Brain stem glioma Usher’s syndrome – Treatment Focal segmental glomerulosclerosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rbl027.2 Potassium Sodium 2-Hydroxylinoleate Eltrombopag Immunoglobulins, Normal Human Sulpiride Fenebrutinib Linezolid TETRODOTOXIN Aon-D21 Cinnarizine Losartan Potassium Mycophenolate Sodium GSK5460025A Glycerol Sufentanil ANX007 REGN7544 Rifabutin Sodium Phosphate More therapies…

    Learn about Your Condition

    Systemic mastocytosis Weaning failure Malignant mast cell neoplasm Ocular melanoma Myelodysplastic syndrome Metastases to meninges Chronic hepatitis B Type IIa hyperlipidaemia Pulmonary embolism Aicardi-Goutieres syndrome Multiple sclerosis relapse Hyperadrenocorticism Autoimmune uveitis Pancreatic carcinoma stage IV Inclusion body myositis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Kyv-101
    • Ocrelizumab
    • Ofatumumab
    Austria Belgium Germany Italy

  • Study on Acetylsalicylic Acid for Colorectal Cancer Patients with PI3K Pathway Mutations

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Acetylsalicylic Acid
    Denmark Finland Norway Sweden

  • Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Rapcabtagene Autoleucel
    • Cyclophosphamide
    • Fludarabine Phosphate
    Austria Belgium Czechia Denmark France Germany +5

  • Study Comparing Two Cisplatin Dosing Schedules with Radiation for Patients with Advanced Head and Neck Cancer

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma
    Investigated Drugs:
    • Cisplatin
    Ireland

  • Study of Spartalizumab and Pazopanib for Patients with Refractory or Recurrent Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pazopanib
    • Spartalizumab
    France

  • Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

    Not yet recruiting

    3 1
    Investigated Drugs:
    • N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3′,5′-Trifluoro[1,1′-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
    Austria Belgium Czechia Denmark Finland France +5
Previous Page
1 … 858 859 860 861 862 … 1,675
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!